BioSpace News Archive

Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence from U.S. Food and Drug Administration (FDA).

Remington Medical, a medical device manufacturing company based in the U.S., announced the launch of VascuChek®, the industry’s first modern wireless, handheld vascular Doppler device for surgical and clinical use.

HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO’s novel drug for pharmacological cardioversion of atrial fibrillation (AF).

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced a new Center of Excellence, located at the Josep Carreras Leukaemia Research Institute and led by Manel Esteller, MD, PhD.

Wilmington, Delaware, United States: Social media platforms enable healthcare facilities and hospitals to connect with potential patients in order to provide valuable information to make the best health decision.

Cell sorting implies the capacity of a technology to segregate cells in a sample based on specific parameters, usually on cell properties.

The global market for orthodontic supplies is primarily driven by factors such as growing number of patients with malocclusions, increasing trend of cosmetic dentistry, tooth decay or tooth loss, jaw diseases, and jaw pain, increasing awareness among the consumers regarding the availability of advanced orthodontic treatments, and increasing disposable income of the expanding population of middle-class.

Wilmington, Delaware, United States: According to the report, the global microscopy devices market was valued at US$ 8.1 Bn in 2020 and is projected to expand at a CAGR of 5.6% from 2017 to 2028.

Scorpion Biological Services, a biopharmaceutical contract development and manufacturing organization and contract research organization, announced the appointment of Stephan Kutzer, Ph.D. as its Interim Chief Executive Officer.

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials.